TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FANAPT

ILOPERIDONE
Neurology Approved 2009-05-06
3
Indications
--
Phase 3 Trials
16
Years on Market

Details

Status
Prescription
First Approved
2009-05-06
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ILOPERIDONE

FANAPT Approval History

Loading approval history...

What FANAPT Treats

2 indications

FANAPT is approved for 2 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Schizophrenia
  • Bipolar I Disorder
Source: FDA Label

FANAPT Boxed Warning

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psych...

Drugs Similar to FANAPT

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ABILIFY ASIMTUFII
ARIPIPRAZOLE
2 shared
OTSUKA
Shared indications:
SchizophreniaBipolar I Disorder
ASENAPINE MALEATE
ASENAPINE MALEATE
2 shared
BRECKENRIDGE
Shared indications:
SchizophreniaBipolar I Disorder
LYBALVI
OLANZAPINE
2 shared
ALKERMES INC
Shared indications:
SchizophreniaBipolar I Disorder
SAPHRIS
ASENAPINE MALEATE
2 shared
AbbVie
Shared indications:
SchizophreniaBipolar I Disorder
ZYPREXA
OLANZAPINE
2 shared
CHEPLAPHARM
Shared indications:
SchizophreniaBipolar I Disorder
ZYPREXA ZYDIS
OLANZAPINE
2 shared
CHEPLAPHARM
Shared indications:
SchizophreniaBipolar I Disorder
ABILIFY MAINTENA KIT
ARIPIPRAZOLE
1 shared
OTSUKA PHARM CO LTD
Shared indications:
Schizophrenia
ADASUVE
LOXAPINE
1 shared
NOVA PNEUMA
Shared indications:
Schizophrenia
ARIPIPRAZOLE
ARIPIPRAZOLE
1 shared
UNICHEM
Shared indications:
Schizophrenia
ARISTADA
ARIPIPRAZOLE LAUROXIL
1 shared
ALKERMES INC
Shared indications:
Schizophrenia
ARISTADA INITIO KIT
ARIPIPRAZOLE LAUROXIL
1 shared
ALKERMES INC
Shared indications:
Schizophrenia
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
Schizophrenia
COBENFY
TROSPIUM CHLORIDE
1 shared
Bristol-Myers Squibb
Shared indications:
Schizophrenia
ERZOFRI
PALIPERIDONE PALMITATE
1 shared
LUYE INNOMIND PHARMA
Shared indications:
Schizophrenia
FLUPHENAZINE DECANOATE
FLUPHENAZINE DECANOATE
1 shared
PH HEALTH
Shared indications:
Schizophrenia
HALOPERIDOL DECANOATE
HALOPERIDOL DECANOATE
1 shared
MANKIND PHARMA
Shared indications:
Schizophrenia
IGALMI
DEXMEDETOMIDINE HYDROCHLORIDE
1 shared
BIOXCEL
Shared indications:
Schizophrenia
INVEGA HAFYERA
PALIPERIDONE PALMITATE
1 shared
Johnson & Johnson
Shared indications:
Schizophrenia
INVEGA SUSTENNA
PALIPERIDONE PALMITATE
1 shared
Johnson & Johnson
Shared indications:
Schizophrenia
INVEGA TRINZA
PALIPERIDONE PALMITATE
1 shared
Johnson & Johnson
Shared indications:
Schizophrenia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FANAPT FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

⚠️ BOXED WARNING

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. FANAPT is not approved for the treatment of patients with dementia-related psychosis [see Warnings and...

FANAPT Patents & Exclusivity

Latest Patent: Dec 2031
Exclusivity: Apr 2027

Patents (392 active)

US9074254 Expires Dec 28, 2031
US9074256 Expires Feb 10, 2031
US9072742 Expires Jan 16, 2031
US9074255 Expires Dec 17, 2030
US8999638 Expires Oct 28, 2030
US8652776 Expires Aug 31, 2030
US9157121 Expires Apr 5, 2030
US8586610 Expires Nov 2, 2027
+ 382 more patents

Exclusivity

I-939 Until Apr 2027
I-939 Until Apr 2027
I-939 Until Apr 2027
I-939 Until Apr 2027
I-939 Until Apr 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.